Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASCO 2021
Research
ASCO: Alpine reports 61% response in trial of CD28 I-O drug
Alpine said that its I-O candidate, a CD28 costimulator, showed early signs of efficacy in tumors that traditionally don't respond to immunotherapy.
Arlene Weintraub
Jun 7, 2021 10:00am
Agendia test spots ultralow breast cancer recurrence risk
Jun 7, 2021 9:30am
Amgen eyes decades of work post-Lumakras approval
Jun 4, 2021 2:00pm
Amgen's stomach cancer drug extends patients' lives in phase 2
Jun 4, 2021 9:00am
Novartis backs up Endocyte buyout with prostate cancer data
Jun 3, 2021 12:40pm
J&J's anti-BCMA CAR-T pads its case ahead of BMS showdown
Jun 1, 2021 8:30am
